Kymera
tumor regressions from substantial degradation of and substrates in preclinical model a | Kymera
Company
Deck Type
IPO
Sector
Industry
Deck date
August 2020
Slide
31 of 49
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
substantial activity in additional arid a mutated solid tumors | Nuvectis Pharma
Nuvectis Pharma
Investor Presentation
July 2023
substantial activity in additional arid a mutated solid tumors | Nuvectis Pharma
SmileDirectClub
Investor Presentation
August 2023
substantial strategic value in vertically integrated business model | SmileDirectClub
Chimerix
Mergers and Acquisitions
January 2021
patient near complete tumor regression | Chimerix
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights